“Non-classical” BRAF mutations may be responsible for tumor cell resistance to vemurafenib and dabrafenib, but increased sensitivity to sorafenib (multi-kinase inhibitor) and MEK inhibitors. The gene discussed is MAP2K7; the disease is neoplasm.